Should I Buy CRDL? CRDL 2026 Analysis

Should You Buy Cardiol Therapeutics Inc (CRDL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.950

1 Day change

-3.06%

52 Week Range

1.590

Analysis Updated At

2026/01/28

CRDL is not a good buy right now for a Beginner long-term investor with $50k–$100k who is impatient and doesn’t want to wait for an optimal entry. The stock is showing weak/indecisive technicals near support, no proprietary buy signals, no near-term news catalysts, and the latest quarter (2025/Q3) still reflects a pre-revenue company with widening losses. I would hold off (avoid initiating a new position today).

Technical Analysis

Price/Trend: Current price is ~0.9826, down -2.09% on the day and trading below the pivot (1.011), which is a mildly bearish setup. Momentum: MACD histogram is slightly positive (0.00122) but ‘positively contracting,’ implying upside momentum is weakening rather than strengthening. RSI: RSI(6) ~40.35 (neutral-to-soft), not indicating an oversold bounce signal. Moving averages: Converging moving averages suggest consolidation/indecision rather than a clear uptrend. Levels: Immediate support is S1 ~0.959 (then S2 ~0.927). Resistance overhead is R1 ~1.063 (then R2 ~1.095). With price below pivot and close to support, risk of a breakdown is meaningful if 0.959 fails.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options snapshot (2025-11-19): Call open interest 19,550 vs put open interest 33, and today’s volume is 167 calls vs 0 puts (put/call ratios read as 0). This shows positioning is heavily call-skewed, but the activity is not broad-based (small absolute volumes). Volatility: 30D implied vol ~119% vs historical vol ~63% (very high IV), consistent with a speculative/biotech-style options market. IV percentile 22 and IV rank 10.41 suggest IV is not at extremes versus its own history, but it’s still high in absolute terms. Sentiment take: Call-heavy open interest/volume can look bullish, but given low put participation and small volumes, it reads more like speculative interest than strong institutional conviction.

Technical Summary

Sell

Buy

Positive Catalysts

and breaks above 1.063, technical sentiment could improve.

Neutral/Negative Catalysts

No recent news catalysts to support a sustained re-rating in the near term (per provided data).
Technical posture is weak-to-neutral: price below pivot and momentum (MACD histogram) is contracting.
High absolute implied volatility signals the market expects large moves, which tends to be unfavorable for beginner long-term investors seeking steadier compounding.
Similarity-based forecast provided: modest odds of small gains short-term, but -2.41% over the next month suggests a soft near-term bias.

Financial Performance

Latest quarter: 2025/Q3. Revenue: 0 (no YoY change; effectively pre-revenue). Net income: -9,964,281 (down -21.72% YoY), indicating losses widened. EPS: -0.12 (down -33.33% YoY), also worsening. Overall: The quarter shows no revenue base and deteriorating profitability metrics, which weakens the long-term ‘easy-to-hold’ case for a beginner investor unless they specifically want high-risk biotech exposure.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating / price target change data was provided, so a Wall Street consensus trend cannot be confirmed here. Pros (typical for early-stage biotech, generalized): upside can be driven by clinical/strategic milestones. Cons (supported by provided financials): pre-revenue profile and widening losses make outcomes more binary and harder to hold comfortably for beginners. Influential/political trading: No recent congress trading data available; hedge funds and insiders are reported as Neutral with no significant recent trends. Intellectia Proprietary Trading Signals: - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

2 Analyst Rating

Wall Street analysts forecast CRDL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDL is 8.5 USD with a low forecast of 8 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.981

Low

Averages

8.5

High

Current: 0.981

Low

Averages

8.5

High

H.C. Wainwright

Buy

initiated

AI Analysis

2025-06-02

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-06-02

initiated

Buy

Reason

H.C. Wainwright initiated coverage of Cardiol Therapeutics with a Buy rating and $9 price target. Cardiol is a clinical-stage company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, the analyst tells investors in a research note. The firm says Cardiol is currently advancing CardiolRx in two lead programs that target recurrent pericarditis and acute myocarditis. It believes investors could soon come to appreciate the value to be unlocked within the company.

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-04-16

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-04-16

Reiterates

Strong Buy

Reason

CRDL Should I Buy

CRDL Should I Buy

Should You Buy Cardiol Therapeutics Inc (CRDL) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch